Silence Therapeutics Plc American Depository Share Financial Ratios
NASDAQ: SLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Silence Therapeutics Plc American Depository Share ratio analysis
Silence Therapeutics Plc American Depository Share earned a net margin of -15851.9% in FY 2025, down from -104.7% a year earlier. Gross margin was 61.5% compared with a median of 59.3% over the prior 3 years. Return on equity reached -142.2%, meaning Silence Therapeutics Plc American Depository Share generated -1.42 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Silence Therapeutics Plc American Depository Share financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Price / sales | 1,558.90 | 23.70 | 61.08 | 68.02 |
| Price / book | 13.99 | 7.65 | 87.89 | 54.11 |
| Gross margin | 61.5% | 72.7% | 59.3% | 37.8% |
| Operating margin | -16,292.8% | -146.4% | -203.5% | -281.9% |
| Net margin | -15,851.9% | -104.7% | -171.4% | -232.4% |
| Free cash flow margin | -11,149.6% | -156.9% | -156.5% | -264.2% |
| Return on equity (ROE) | -142.2% | -33.8% | -246.6% | -184.9% |
| Return on assets (ROA) | -67.4% | -22.4% | -45.4% | — |
| Current ratio | 8.72 | 11.14 | 4.62 | — |
| Revenue growth | -98.7% | 36.7% | 46.1% | — |